Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from...

Industry: Biotechnology

Sector: Healthcare

Website: www.biomx.com

Address:

850 New Burton Road, Suite 201, Dover, United States

forsiz1 Jun. 5 at 4:43 AM

$PHGE PATIENCE !!! BIGGER MOVE COMING $10

0 · Reply

Sw1ngb0t Jun. 5 at 12:14 AM

$PHGE 👀

0 · Reply

Sw1ngb0t Jun. 4 at 11:55 PM

$TGHL $PRFX $PHGE $SKLZ $SPRC gaps on some that might fill tomorrow... be ready

0 · Reply

DragonOfBosnia Jun. 4 at 4:05 PM

$AMZE $DFNS $PHGE told you

2 · Reply

ieatbaguette Jun. 4 at 2:57 PM

$PHGE

0 · Reply

cycloon Jun. 4 at 11:46 AM

$PHGE Time is running out; it could happen any moment now.

1 · Reply

Sw1ngb0t Jun. 4 at 11:43 AM

$PRFX $TGHL $SKLZ $SPRC $PHGE tick tock shorties... these are all the same. wear protection

0 · Reply

Sw1ngb0t Jun. 3 at 11:50 PM

$PHGE could do the big move any day

0 · Reply

Sw1ngb0t Jun. 3 at 8:12 PM

$PRFX $TGHL $SKLZ $SPRC $PHGE

0 · Reply

The_Big_Dirdy Jun. 3 at 7:12 PM

$PHGE Low volume today.

0 · Reply

BiomX appoints Gabby Sarusi as strategic advisor

Jun 2, 2026, 9:32 AM EDT - 2 days ago

Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

Jun 1, 2026, 9:25 AM EDT - 3 days ago

Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence

2026-05-27T15:22:44.000Z - 8 days ago

BiomX names Roy Timor-Rousso as Chief Business Officer

May 27, 2026, 9:40 AM EDT - 8 days ago

BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

May 20, 2026, 4:00 PM EDT - 15 days ago

BiomX Quarterly report: Q1 2026

May 6, 2026, 4:15 PM EDT - 4 weeks ago

BiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand

Apr 16, 2026, 4:30 PM EDT - 7 weeks ago

Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems

Apr 13, 2026, 9:20 AM EDT - 7 weeks ago

BiomX Accelerates Defense Technology Buildout with DFSL Acquisition

Apr 10, 2026, 8:30 AM EDT - 7 weeks ago

BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

2026-04-09T18:36:16.000Z - 2 months ago

Biomx Inc trading halted, news pending

2026-04-01T14:10:15.000Z - 2 months ago

Biomx Inc trading resumes

2026-04-01T13:38:15.000Z - 2 months ago

Biomx Inc trading halted, news pending

Mar 31, 2026, 10:48 AM EDT - 2 months ago

BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

Mar 30, 2026, 9:28 AM EDT - 2 months ago

BiomX Adds Former Mossad Deputy to Advisory Board

2026-03-27T20:40:15.000Z - 2 months ago

BiomX receives noncompliance notification from Nasdaq

Mar 27, 2026, 4:30 PM EDT - 2 months ago

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

2026-03-26T13:08:14.000Z - 2 months ago

BiomX launches X Security & Defense subsidiary in Israel

Mar 26, 2026, 8:48 AM EDT - 2 months ago

BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

Mar 25, 2026, 8:00 AM EDT - 2 months ago

BiomX Proxy statement: Proxy filing

2026-03-19T13:20:44.000Z - 2 months ago

BiomX issues letter to shareholders

Mar 19, 2026, 9:15 AM EDT - 2 months ago

BiomX CEO Issues Letter to Stockholders

Mar 11, 2026, 8:00 AM EDT - 3 months ago

BiomX Transcript: EGM 2026

2026-03-09T14:55:29.000Z - 3 months ago

BiomX downgraded to Neutral from Buy at H.C. Wainwright

2026-03-09T13:07:20.000Z - 3 months ago

BiomX names Michael Oster as CEO, David Rokach as CFO

Mar 9, 2026, 9:00 AM EDT - 3 months ago

BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

2026-03-05T16:00:36.000Z - 3 months ago

Biomx Inc trading resumes

2026-03-05T15:55:32.000Z - 3 months ago

Biomx Inc trading halted, volatility trading pause

Feb 25, 2026, 8:00 AM EST - 3 months ago

BiomX Transcript: EGM 2026

Feb 19, 2026, 7:00 AM EST - 3 months ago

BiomX Annual report: Q4 2025

Feb 13, 2026, 7:00 AM EST - 3 months ago

BiomX Proxy statement: Proxy Filing

2026-02-09T21:40:33.000Z - 4 months ago

BiomX files to sell 5.31M shares of common stock for holders

Feb 9, 2026, 7:00 AM EST - 4 months ago

BiomX Registration statement: Registration Filing

Feb 3, 2026, 7:00 AM EST - 4 months ago

BiomX Proxy statement: Proxy Filing

2026-01-29T14:50:55.000Z - 4 months ago

Biomx Inc trading resumes

2026-01-29T14:46:29.000Z - 4 months ago

Biomx Inc trading halted, volatility trading pause

Jan 27, 2026, 1:41 PM EST - 4 months ago

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

2025-12-29T13:15:13.000Z - 5 months ago

BiomX announces $3M private placement

Dec 29, 2025, 8:00 AM EST - 5 months ago

BiomX Announces $3.0 Million Private Placement

2025-12-08T12:36:04.000Z - 6 months ago

BiomX discontinues Phase 2b BX004 trial, plans cost-cutting measures

2025-11-25T21:45:24.000Z - 6 months ago

BiomX provides update on BX004 Phase 2b trial in Cystic Fibrosis

Nov 25, 2025, 4:40 PM EST - 6 months ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

2025-11-25T11:10:33.000Z - 6 months ago

BiomX price target adjusted to $26 from $15 at H.C. Wainwright

Nov 12, 2025, 8:30 AM EST - 7 months ago

BiomX Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 7 months ago

BiomX Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 7 months ago

BiomX Earnings release: Q3 2025

Nov 12, 2025, 7:30 AM EST - 7 months ago

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

Oct 17, 2025, 8:30 AM EDT - 8 months ago

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Aug 28, 2025, 8:00 AM EDT - 10 months ago

BiomX Proxy statement: Proxy Filing

Aug 28, 2025, 8:00 AM EDT - 10 months ago

BiomX Proxy statement: Proxy Filing

Aug 19, 2025, 8:19 AM EDT - 10 months ago

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Aug 15, 2025, 8:00 AM EDT - 10 months ago

BiomX Proxy statement: Proxy Filing

Aug 13, 2025, 8:00 AM EDT - 10 months ago

BiomX Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

BiomX Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

BiomX Earnings release: Q2 2025

Aug 13, 2025, 6:30 AM EDT - 10 months ago

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Aug 6, 2025, 8:30 AM EDT - 10 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Jul 14, 2025, 9:00 AM EDT - 11 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 8, 2025, 8:30 AM EDT - 11 months ago

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025, 10:02 AM EDT - 1 year ago

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 2:00 PM EDT - 1 year ago

BiomX Earnings Call Transcript: Q1 2025

May 15, 2025, 2:00 PM EDT - 1 year ago

BiomX Quarterly report: Q1 2025

May 15, 2025, 2:00 PM EDT - 1 year ago

BiomX Earnings release: Q1 2025

May 15, 2025, 6:30 AM EDT - 1 year ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 1 year ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

BiomX Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

BiomX Registration statement: Registration Filing

Apr 3, 2025, 11:00 AM EDT - 1 year ago

BiomX Transcript: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

BiomX Proxy statement: Proxy Filing

Apr 1, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 9:00 AM EDT - 1 year ago

BiomX Earnings Call Transcript: Q4 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

BiomX Annual report: Q4 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

BiomX Earnings release: Q4 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

BiomX Slides: Q4 2024

Mar 31, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BiomX Proxy statement: Proxy Filing

Mar 25, 2025, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 1 year ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 17, 2025, 8:00 AM EDT - 1 year ago

BiomX Proxy statement: Proxy Filing

Nov 14, 2024, 8:00 AM EST - 1 year ago

BiomX Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BiomX Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BiomX Earnings release: Q3 2024

Nov 14, 2024, 6:30 AM EST - 1 year ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 1 year ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

BiomX Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 1 year ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 8:00 AM EDT - 1 year ago

BiomX Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 1 year ago

BiomX Quarterly report: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 1 year ago

BiomX Earnings release: Q2 2024

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 29, 2024, 7:00 AM EDT - 2 years ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 11, 2024, 8:00 AM EDT - 2 years ago

BiomX Registration statement: Registration Filing

Jul 10, 2024, 6:30 AM EDT - 2 years ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

Jul 9, 2024, 8:00 AM EDT - 2 years ago

BiomX Registration statement: Registration Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

BiomX Proxy statement: Proxy Filing

Jun 13, 2024, 8:00 AM EDT - 2 years ago

BiomX Proxy statement: Proxy Filing

May 30, 2024, 4:50 PM EDT - 2 years ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 2 years ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 28, 2024, 8:00 AM EDT - 2 years ago

BiomX Proxy statement: Proxy Filing

May 21, 2024, 8:00 AM EDT - 2 years ago

BiomX Earnings Call Transcript: Q1 2024

May 21, 2024, 8:00 AM EDT - 2 years ago

BiomX Earnings release: Q1 2024

May 21, 2024, 8:00 AM EDT - 2 years ago

BiomX Quarterly report: Q1 2024

May 21, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 2 years ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

BiomX Registration statement: Registration Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 2 years ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 8:00 AM EDT - 2 years ago

BiomX Earnings Call Transcript: Q4 2023

Apr 3, 2024, 8:00 AM EDT - 2 years ago

BiomX Annual report: Q4 2023

Apr 3, 2024, 8:00 AM EDT - 2 years ago

BiomX Earnings release: Q4 2023

Apr 3, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 2 years ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 2 years ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

forsiz1 Jun. 5 at 4:43 AM

$PHGE PATIENCE !!! BIGGER MOVE COMING $10

0 · Reply

Sw1ngb0t Jun. 5 at 12:14 AM

$PHGE 👀

0 · Reply

Sw1ngb0t Jun. 4 at 11:55 PM

$TGHL $PRFX $PHGE $SKLZ $SPRC gaps on some that might fill tomorrow... be ready

0 · Reply

DragonOfBosnia Jun. 4 at 4:05 PM

$AMZE $DFNS $PHGE told you

2 · Reply

ieatbaguette Jun. 4 at 2:57 PM

$PHGE

0 · Reply

cycloon Jun. 4 at 11:46 AM

$PHGE Time is running out; it could happen any moment now.

1 · Reply

Sw1ngb0t Jun. 4 at 11:43 AM

$PRFX $TGHL $SKLZ $SPRC $PHGE tick tock shorties... these are all the same. wear protection

0 · Reply

Sw1ngb0t Jun. 3 at 11:50 PM

$PHGE could do the big move any day

0 · Reply

Sw1ngb0t Jun. 3 at 8:12 PM

$PRFX $TGHL $SKLZ $SPRC $PHGE

0 · Reply

The_Big_Dirdy Jun. 3 at 7:12 PM

$PHGE Low volume today.

0 · Reply

IntentionalTrades Jun. 3 at 5:03 PM

$PHGE Riding this back from $.75. Learn to start your position in red after performing your DD.

0 · Reply

Maximusprime69 Jun. 3 at 4:42 PM

$PHGE 👀

0 · Reply

avis2021 Jun. 3 at 4:11 PM

$PHGE

0 · Reply

Sw1ngb0t Jun. 3 at 3:29 PM

$PHGE probably a good place to buy. I'd say it will bounce by end of day

0 · Reply

Zskylar Jun. 3 at 2:38 PM

$PHGE bounce needed

0 · Reply

cycloon Jun. 3 at 7:51 AM

$PHGE BiomX (NYSE American: PHGE) appointed Prof. Gabby Sarusi as Strategic Advisor on June 2, 2026. He will support expansion into defense, security, critical infrastructure, and first-response sectors, advising on technology evaluation and long-term growth strategy. Prof. Sarusi brings senior defense-industry, academic, board, and entrepreneurial experience in advanced imaging and sensing systems.

0 · Reply

Bigmatt89 Jun. 3 at 3:27 AM

$PHGE if you’re losing money here buy AMFN. Will be dollars soon.NFA GLTA

0 · Reply

Sw1ngb0t Jun. 3 at 1:42 AM

$PHGE bounce at 0.75 I'd say

0 · Reply

avis2021 Jun. 3 at 12:42 AM

$PHGE great entry... Let's go higher

0 · Reply

Sw1ngb0t Jun. 2 at 11:42 PM

$PRFX $TGHL $SKLZ $SPRC $PHGE good ones

0 · Reply

avis2021 Jun. 2 at 7:39 PM

$PHGE with news, this will fly .. $2+ happen last week.. shorts will suffer the most

0 · Reply

DragonOfBosnia Jun. 2 at 7:33 PM

$AMZE $DFNS $PHGE all 3 down hard, don’t touch anything 🧃 or toff

1 · Reply

Market Cap	8.81M
Revenue (ttm)	0.00
Net Income (ttm)	-36.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	709,700
Avg Vol	7,298,926
Day's Range	N/A - N/A
Shares Out	10.15M
Stochastic %K	16%
Beta	1.18
Analysts	Hold
Price Target	$26.00